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Short Communication
Chemokine-Induced Secretion of Gelatinase B in
Primary Human Monocytes
These enzymes are active during tissue development and
differentiation, cellular infiltration and wound healing (Na-
gase, 1997; Nagase and Woessner, 1999). MMPs have
also been implicated in chronic disease processes such
as multiple sclerosis and rheumatoid arthritis, as well as
in tumor progression and metastasis (Stetler-Stevenson
et al., 1993a; Murphy and Gavrilovic, 1999).
Based upon their substrate specificity and cellular lo-
cation, the MMPs have been ascribed to select sub-
groups. These groups include the collagenases,
stromelysins, gelatinases and membrane-bound matrix
metalloproteinases (MT-MMP) (Nagase, 1997; Nagase
and Woessner, 1999). The endogenous tissue inhibitors
of matrix metalloproteinases, or TIMPs, regulate the en-
zymatic activity of MMPs. To date, four TIMP proteins
(TIMP-1, 2, 3, and 4) have been described (Nagase and
Woessner, 1999; Brew et al., 2000). A balance between
MMP and TIMP protein interactions is thought to help
control the functional activity of MMPs in vivo (Murphy
and Gavrilovic, 1999; Nagase and Woessner, 1999).
Chemokines help direct the influx and migration of se-
lect immune effector cells, while MMPs are involved in
the breakdown of the extracellular matrix (Stuve et al.,
1996; Ozenci et al., 1999; Nelson and Krensky, 2001). Re-
cent observations have highlighted the biological linkage
between these two families of proteins (Nelson and Kren-
sky, 2001). For example, the functional activity of
chemokines can be modified through post-translational
proteolytic processing. Cleavage of MCP-3/CCL7 by the
matrix metalloproteinase gelatinase A (MMP2) generates
a product that binds to the chemokine receptors CCR1,
CCR2, and CCR3 and acts as a potent antagonist that
suppresses inflammation, thus demonstrating that matrix
metalloproteinases can act both as effectors and regula-
tors of the inflammatory response (McQuibban et al.,
2000).
Since chemokines direct leukocyte migration it has
been proposed that they may also control the production
of MMPs by migrating monocytes. MMPs in general, and
specifically the gelatinases A (MMP-2) and B (MMP-9),
are thought to be of pivotal importance in leukocyte ex-
travasation (Nagase and Woessner, 1999). Monocytes
are equipped with a series of chemokine receptors that
control their normal trafficking as well as migration during
inflammation. We hypothesized that chemokines that
elicit monocyte migration may also control production of
the MMPs required for extravasation. This question was
pursued from two biological perspectives. The first fo-
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Chemokines help control normal leukocyte traffick-
ing as well as their infiltration into tissues during
acute and chronic inflammation. Matrix metallopro-
teinases (MMPs) help support the extravasation and
infiltration of leukocytes through limited proteolysis
of basement membranes and matrix material. The ef-
fect of the chemokines RANTES/CCL5, MCP-1/CCL
and SDF-1/CXCL12 on secretion of the matrix metal-
loproteinase B and its endogenous inhibitor TIMP-1
was studied. RANTES/CCL5 and SDF-1/CXCL12
were found to induce MMP-9 secretion in primary hu-
man monocytes while TIMP-1 secretion was not
affected. RANTES/CCL5 effects were mediated
through CCR1 because the CCR1 antagonist BX471
was found to effectively block RANTES/CCL5-in-
duced MMP-9 secretion.
Key words: BX471 /CCR1 /CXCR4 /MMP-9 /RANTES /
TIMP-1.
Chemokines are a large family of chemotactic cytokines
that control diverse biological actions including cellular
trafficking, hematopoiesis and angiogenesis (Nelson and
Krensky, 2001). Select chemokines control acute and
chronic inflammatory processes such as those found in
rheumatoid arthritis (DeVries et al., 1999), allograft trans-
plant rejection (Grone et al., 1999; Horuk et al., 2001; Nel-
son and Krensky, 2001) and multiple sclerosis (Ranso-
hoff, 1999). In addition, chemokines and their receptors
have been implicated in tumor growth and metastasis
(Muller et al., 2001).
The matrix metalloproteinases (MMPs) play critical
roles in health and disease and are represented by at
least 20 extracellular matrix degrading metallo endopeti-
dases (Nagase, 1997; Nagase and Woessner, 1999).
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stimulation of CD34+ cells has recently been described
(Janowska-Wieczorek et al., 2000).
The natural inhibitor for MMP-9 is TIMP-1 (Nagase and
Woessner, 1999). Analysis of conditioned medium using
a TIMP-1-specific ELISA (Amersham Pharmacia,
Freiburg, Germany) showed no significant effect on
TIMP-1 secretion following chemokine stimulation (Fig-
ure 3B). FACS analysis of the monocytes also showed no
increase in surface expression of TIMP-1 following
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Fig. 1 FACS Analysis of Cell Surface Chemokine Receptor Ex-
pression on Monocytes.
Flow cytometric analysis was performed as described (Mack et
al., 2000; Weber et al., 2001). Freshly isolated monocytes were
stained with antibodies directed against a series of chemokine
receptors, MMP-9 and TIMP-1. (A) CCR1, MAB145 (R&D Sys-
tems, Wiesbaden, Germany); (B) CCR5, mAB clone MC-1 kindly
provided by Dr. M. Mack (Ludwig-Maximilans-University, Mu-
nich, Germany); (C) CCR2, MAB 150 (R&D Systems); (D) CXCR4,
MAB 170 clone # 12G5 (R&D Systems); (E) MMP-9, IM09L (Cal-
biochem-Novabiochem GmbH, Bad Soden, Germany); and (F)
TIMP-1, IM32L (Calbiochem-Novabiochem). Data are ex-
pressed as overlay histogram analysis of specific anti-CCR or
CXCR signal (bold line) and isotype control (thin line).
cused on chemokines/chemokine receptors that control
normal monocyte trafficking – independent of inflamma-
tion. The second focused on chemokines and receptors
linked to monocyte infiltration during acute and chronic
inflammatory processes.
Freshly isolated peripheral blood monocytes were first
characterized for chemokine receptor, gelatinase B
(MMP-9), and TIMP-1 expression. The cells were then
stimulated with various concentrations of appropriate
chemokine ligands. Consistent with earlier reports, fresh-
ly isolated human peripheral blood monocytes were
found to express the chemokine receptors CCR1, CCR2
and CXCR4 as assessed by fluorescence-assisted cell
sorting (FACS; Figure 1A, C and D) and PCR analysis
(Mack et al., 2000; Weber et al., 2001). CCR1 and CCR2
are proinflammatory chemokine receptors, while the re-
ceptor CXCR4 is involved in leukocyte homeostasis (Nel-
son and Krensky, 2001). The receptor CCR5 was found to
be upregulated on the monocytes but only after incuba-
tion/activation on plastic for 24 hours (data not shown).
The primary monocytes also strongly expressed MMP-9
and TIMP-1 on their surface (Figure 1E and F).
The monocytes (200 000 cells/well) were treated with
increasing concentrations of chemokines that target the
various chemokine receptors: RANTES/CCL5; CCR1,
MCP-1/CCL2; CCR2, and SDF-1/CXCL12; CXCR4. The
resultant conditioned culture medium was analyzed by
gelatin-zymography (Figure 2). Stimulation with TNF-α
(10 ng/ml) served as a positive control for induced MMP
production (Zhang et al., 1998). Analysis revealed that the
chemokines RANTES/CCL5 and SDF-1/CXCL12 both in-
duced a release of pro-MMP-9 (Figure 2). A variable re-
sponse was also seen with MCP-1. Maximum MMP-9
protein secretion was observed after 24 to 36 hours of
chemokine incubation as tested over a range of 48 h
(data not shown). No secretion of MMP-2 (gelatinase A)
protein was seen.
To quantify the MMP-9 protein secreted into the cul-
ture medium, an MMP-9-specific substrate assay was
employed. MMP-9 protein could be assessed by the
substrate assay only after activation of the conditioned
medium with p-aminophenyl mercuric acetate (APMA),
demonstrating the secretion of pro-MMP-9 by the mono-
cytes. Again, RANTES/CCL5 and SDF-1/CXCL12 were
found to induce pro-MMP-9 production (Figure 3A).
Stimulation with 200 ng/ml RANTES/CCL5 or SDF-
1/CXCL12 represented the maximal level of stimulation
seen and resulted in a 5- and 7-fold increased secretion
of pro-MMP-9 protein, respectively (Figure 3A).
The MCP-1-induced expression of MMP-9 by mono-
cytes has been previously described (Vos et al., 2000). In
the experiments detailed here, a slight increase of MMP-
9 secretion was sometimes seen following MCP-1 stimu-
lation. However, these results were not consistent. Es-
sentially no increase in pro-MMP-9 secretion was seen in
three separate experiments, an increase (up to 3.5-fold
as determined by MMP-9 substrate assay) was found in
two experiments. An increase of MMP-9 after SDF-1
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(Corcoran et al., 1995) and MMP-3 (Shapiro et al., 1990).
Analysis of conditioned medium by MMP-1 or MMP-3
Biotrak ELISA (Amersham Pharmacia) could not demon-
strate RANTES-induced secretion of MMP-1 nor of
MMP-3 in the primary monocytes (data not shown). How-
ever, ‘activated’ (24 hours on plastic) monocytes did
show low levels of MMP-3 by ELISA (data not shown).
This is in contrast to recently published findings (Borzi et
al., 2000) describing RANTES/CCL5-induced secretion
of MMP-3 at a level above 1000 ng/ml in normal and os-
teoarthritic chondrocytes.
Primary monocytes can in theory bind RANTES/CCL5
through at least two chemokine receptors, CCR1 and
CCR5 (Nelson and Krensky, 2001). Freshly isolated
monocytes do not express CCR3, an additional
RANTES/CCL5 receptor, as assessed by FACS analysis
and RT-PCR (Weber et al., 2001) but do strongly express
CCR1 (Figure 1). CCR5 is not expressed by freshly isolat-
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Fig. 2 Chemokine-Induced Secretion of proMMP-9 in Primary Monocytes.
Gelatin-zymogram of RANTES/CCL5-induced secretion of pro-MMP-9. Monocytes were isolated from EDTA-blood of healthy volun-
teers as described (Weber et al., 2001) and cultured in Macrophage SFM (Gibco-BRL Life Technologies, Karlsruhe, Germany) at a densi-
ty of 1.5 – 2.0 × 106 cells/ml in 96-well plates (Costar Corning, Cambridge MA, USA). Cells were stimulated as shown with RANTES/CCL5,
MCP-1/CCL2, SDF-1/CXCL12 or TNF-α (all from TEBU, Frankfurt, Germany) for 24 h. Conditioned media were stored at – 20 °C.
The concentrations of chemokines used (between 10 and 200 ng/ml) represent the general range of protein concentrations used to es-
tablish optimal chemotactic parameters for chemokine induced migration of primary monocytes (Horuk and Ng, 2000; Weber et al., 2001).
The media supernatants from monocytes were mixed with 2 × loading buffer (Invitrogen, Groningen, Netherlands). Proteins were sepa-
rated on a precast 10% Tris-glycine gel containing 0.1% gelatin (Invitrogen). Following electrophoreses, renaturing and developing was
performed according to manufacturer’s recommendation. Gel development was stopped after 3 to 5 hours of incubation at 37 °C.
Equivalent results were obtained in three independent experiments.
Fig. 3 Quantification of Chemokine-Induced Secretion of
MMP-9 and TIMP-1 Proteins.
Cells were cultured in Macrophage SFM at a density of 1.5 – 2.0
× 106 cells/ml for 24 h. Conditioned media were harvested and
stored at – 20 °C.
(A) Quantitation of chemokine-induced pro-MMP-9 in the condi-
tioned medium was analyzed by an MMP-9 substrate assay
#RPN 2634 (Amersham Pharmacia) according to manufacturers
recommendations for the detection of 0.125 – 4.0 ng/ml MMP-9
protein. The results presented are an average from two values.
Essentially equivalent results were obtained in three independ-
ent experiments.
(B) TIMP-1 protein was measured using a specific ELISA #RPN
6211 (Amersham Pharmacia) following manufacturers recom-
mendations. Absorbance at 450nm was read via an Emax Elisa
Reader (Molecular Devices, Ismaning/Munich, Germany) and an-
alyzed with Softmax®pro analysis software (Molecular Devices).
The values presented are an average of parallel measurements
and represent the results seen in three independant experiments.
chemokine stimulation (data not shown). Analysis of
MMP-9 mRNA expression after stimulation with
RANTES/CCL5 by real time RT-PCR (TaqMan, Perkin
Elmer-ABI, Weiterstadt, Germany) revealed a 2.4-fold in-
crease in steady-state mRNA expression after stimula-
tion with RANTES/CCL5, demonstrating control at the
mRNA level (data not shown).
Macrophages have been reported to secrete MMP-1
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ed monocytes (Figure 1), but is upregulated upon activa-
tion (Mack et al., 2000; Weber et al., 2001).
The chemokine receptor CCR1 has been identified as
a potential therapeutic target for control of acute and
chronic inflammation through a selective blockade of
leukocyte recruitment (Grone et al., 1999; Horuk et al.,
2001; Nelson and Krensky, 2001). To demonstrate the
role of CCR1 in the RANTES/CCL5-induced upregulation
and secretion of MMP-9 by monocytes, a biologically ac-
tive non-peptide antagonist (BX 471) directed against
CCR1 was employed (Horuk et al., 2001).
Following preincubation of monocytes with BX 471 (10
µM), the cells were stimulated with RANTES/CCL5 for 24
h. Secretion of pro-MMP-9 was assessed both by gelatin-
zymography (Figure 4A) and MMP-9 substrate assay (Fig-
ure 4B). TNF-α (10 ng/ml) stimulation served as positive
control. In comparison to vehicle control (DMSO), the
CCR1 antagonist caused a significant reduction of MMP-
9 release into the culture medium (Figure 4A). Release of
TNF-α induced MMP-9 was not affected by BX 471
(Figure 4A). The essentially complete blockage of
RANTES/CCL5-induced secretion of pro-MMP-9 by BX
471 clearly demonstrates the importance of CCR1 in me-
diating the RANTES/CCL5-induced secretion of MMP-9.
The slight reduction in constitutive MMP-9 secretion seen
in the absence of RANTES/CCL5 stimulation may be due
to the low constitutive expression of RANTES/CCL5 seen
in freshly isolated human monocytes (data not shown).
Analysis of the specialized roles of apparently redun-
dant chemokine receptors has demonstrated the central
importance of CCR1 in the direct recruitment of mono-
cytes from the peripheral circulation (Weber et al., 2001).
During inflammation chemokines such as RANTES/CCL5
may help induce the production of MMP-9 by infiltrating
CCR1-expressing monocytes. Thus, a selective block-
ade of CCR1 may help control tissue damage in part,
through suppression of MMP-9 production. To this end,
CCR1 antagonists have been shown to dramatically re-
duce the tissue damage associated with allograft trans-
plant rejection and multiple sclerosis (Grone et al., 1999;
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Fig. 4 Effect of the Anti-CCR1 Antagonist BX 471 on RANTES-Induced Secretion of MMP-9.
Freshly isolated monocytes were preincubated with BX 471 (10 µM) for 10 min followed by stimulation with increasing concentrations of
RANTES/CCL5 (see Figure) or TNF-α (10 ng/ml) in Macrophage SFM at a density of 1.5 – 2.0 × 106 cells/ml for 24 h. Conditioned medi-
um was harvested and stored at – 20 °C for further analysis.
(A) Gelatine zymogram of conditioned medium.
(B) Quantification of MMP-9 concentration by MMP-9 substrate assay. Results presented are the average of three determinations + the
standard error of the mean. Results were confirmed in three independant experiments.
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Horuk and Ng, 2000; Horuk et al., 2001; Nelson and Kren-
sky, 2001).
Tumor expression of RANTES/CCL5 has been linked
to ‘aggressiveness’ of breast carcinoma (Luboshits et al.,
1999). Increased production of RANTES/CCL5 by the tu-
mor correlates with a more advanced stage of the dis-
ease. Breast cancer staging has also been associated
with increased mononuclear cell infiltration (Urdiales-
Viedma et al., 1986). Furthermore, it is recognized that
MMP activity is involved in the control of tumor growth
and metastasis (Stetler-Stevenson et al., 1993b; Nagase
and Woessner, 1999). Based upon the results presented
here, one could speculate that RANTES-induced attrac-
tion and activation of monocytes may lead to MMP-9
mediated degradation of the extracellular matrix sur-
rounding the tumor tissue, thereby promoting tumor pro-
liferation, and potentially, tumor escape.
We have further shown that the homeostatic chemo-
kine SDF-1/CXCL12, acting through CXCR4, can moder-
ate MMP-9 production by primary monocytes, a me-
chanism that may be important to normal monocyte
trafficking. Interestingly, a recent report has demonstrat-
ed the importance of CXCR4 expression by breast can-
cer cells in promoting tumor metastasis to bone marrow.
If the metastatic tumor cell behaves in a manner analo-
gous to that seen in monocytes, then SDF-1 may also di-
rectly induce MMP production by these cells, thus facili-
tating tumor cell egress and invasion of other SDF-1
expressing tissues.
The results presented here suggest that chemokine re-
ceptor blockade may limit tissue damage by suppressing
MMP production, and may in addition help limit tumor
progression.
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